# Passage BIO, Inc.: overview PASG · Nasdaq · CIK 1787297 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/pasg.md) · [Financials](/companies/pasg/financials.md) · [Filings](/companies/pasg/filings.md) · [Insiders](/companies/pasg/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(6.15)](/filings/0001104659-25-109180.md) | not reported | [(4.87)](/filings/0001104659-26-058987.md) | [(2.96)](/filings/0001104659-26-093021.md) | [(2.44)](/filings/0001104659-25-109180.md) | not reported | [(2.36)](/filings/0001104659-26-058987.md) | [(2.44)](/filings/0001104659-26-093021.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(3.48)](/filings/0001558370-23-002833.md) | [(2.50)](/filings/0001558370-24-002310.md) | [(1.86)](/filings/0001558370-25-002101.md) | [(21.04)](/filings/0001104659-26-022549.md) | [(14.35)](/filings/0001104659-26-022549.md) | | Free cash flow | $m | not reported | not reported | not reported | [(48.0)](/filings/0001104659-26-022549.md) | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/pasg/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $4.3m | 2,886,125 | | New +2,886,125 | | [Lynx1 Capital Management LP](/funds/1910456.md) | 2026-06-30 | $3.3m | 673,759 | | Added +50,055 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $556.1k | 113,964 | | Unchanged | | [Balyasny Asset Management L.P.](/funds/1218710.md) | 2026-06-30 | $522.3k | 107,025 | | New +107,025 | | [Ikarian Capital, LLC](/funds/1778253.md) | 2026-06-30 | $485.6k | 99,517 | | Added +31,393 | | [Yiheng Capital Management, L.P.](/funds/1447228.md) | 2026-06-30 | $420.2k | 86,097 | | Unchanged | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $233.7k | 47,892 | | Reduced −85,720 | | [Erste Asset Management GmbH](/funds/2024532.md) | 2026-06-30 | $197.2k | 40,665 | | Reduced −44,597 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $180.7k | 37,026 | | Reduced −4,354 | | [Verdad Advisers, LP](/funds/1812822.md) | 2026-06-30 | $150.0k | 30,728 | | Added +8,600 | ## Recent filings [All 442 filings](/companies/pasg/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-03 | 01:37 ET | [8-K](/filings/0001140361-26-035515.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001140361-26-035515 | | 2026-08-10 | 11:15 ET | [10-Q](/filings/0001104659-26-093021.md) | Quarterly report, period 2026-06-30 | 0001104659-26-093021 | | 2026-07-02 | 01:19 ET | [SCHEDULE 13D](/filings/0000902664-26-003000.md) | Ownership report, active investor | 0000902664-26-003000 | | 2026-06-24 | 20:15 ET | [8-K](/filings/0001104659-26-077306.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 3.02 Unregistered sale of equity; 5.01 Change in control; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-077306 | | 2026-05-27 | 20:15 ET | [8-K](/filings/0001104659-26-066956.md) | 1.02 Termination of a material agreement | 0001104659-26-066956 | | 2026-05-26 | 11:15 ET | [8-K](/filings/0001104659-26-065991.md) | 5.07 Shareholder vote results | 0001104659-26-065991 | | 2026-05-12 | 11:01 ET | [10-Q](/filings/0001104659-26-058987.md) | Quarterly report, period 2026-03-31 | 0001104659-26-058987 | | 2026-04-28 | 11:00 ET | [8-K](/filings/0001104659-26-049755.md) | 2.05 Exit or disposal costs | 0001104659-26-049755 | | 2026-04-20 | 11:15 ET | [8-K](/filings/0001104659-26-045219.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-045219 | | 2026-04-07 | 11:00 ET | [DEF 14A](/filings/0001104659-26-040130.md) | Proxy statement, period 2026-05-19 | 0001104659-26-040130 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-022549.md), filed Mar 3, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1787297 - Tickers: PASG - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.